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thediagnosisof coronary mperhwkn and ceoc- 
clusion after thrombdysis. In particular, the 
value of serial l&lead electmcardiographk 
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tinuous muRUead computer-assisted ECG moni- 
todng is compared. Regarding the serum pro- 
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E arly reperfusion and sustained patency of the infarct-related coronary artery are im- portant determinants of survival.’ Thus, 
more aggressive therapy may be indicated if throm- 
bolytic therapy fails to open the occluded vessel or 
if reocclusion of an initially reperfused coronary 
artery occurs. In contrast, administration of throm- 
bolytic agents may be discontinued to minimize 
bleeding risk in patients with a rapidly reperfused 
artery. In this manner, therapy of acute myocardial 
infarction can be tailored to the status of the 
infarct-related vessel. In order to guide therapy, 
continuous monitoring of the vessel status is 
mandatory. Coronary angiography is the “gold 
standard” to assess patency and occlusion or reoc- 
elusion. However, angiography supplies only very 
momentary information on the status of the infarct- 
related vessel, and this invasive technique is not 
useful for continuous monitoring. 
Noninvasive methods for monitoring reperfu- 
sion of the infarct-related vessel include clinical 
markers (such as resolution of chest pain), electro- 
cardiographic (ECG) findings (such as the occur- 
rence of accelerated idioventricular rhythm and 
normalization of the ST segment), and monitoring 
of specific cardiac proteins in plasma.2-5 Resolu- 
tion of chest pain is very subjective and may 
frequently be related to analgesic medication. Cer- 
tain arrhythmias suggesting reperfusion are spe- 
cific, but not sufficiently sensitive, actually to detect 
reperfusion. Thus, neither of these 2 methods can 
be used to predict reliably coronary vessel status. 
In this overview, use of continuous multilead ECG 
monitoring and of monitoring of myocardial pro- 
teins in serum is discussed. 
ROLE OF THE ELECTROCAR MOGRAM FOR 
DETECTION OF REPERFUSION AND PATENCY 
Following reperfusion, as documented by coro- 
nary angiography, resolution of ST-segment eleva- 
tion occurs earlier, with an almost 5-fold faster 
time course than the changes associated with the 
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TABLE I Serial 12 Lead Electrocardiographic Recording to Predict Coronary Reperfusion After Thrombolysis Therapy* 
Positive/ 
No. ECGs/ Interval Pt. with Sensi- Speci- Negative 
Assessment Thrombolysis No. Criteria tivity ficity Predictive Comment 
Study Criteria Interval Angiography Pt. 1%) (%) (%) Value f%) on Study 
Kircher et al3 ? 4 average ST elevation, 2 ECGs/90 min 90 min 56 34 52 88 88/46 Correct study design but 
2 worst leads criteria not defined 
Clemmensen 220% $ I ST elevations 2 ECGs/lBO min 180min 53 62 88 80 88/80 Correct study design, best 
et aIll serial ECG study 
Saran et alI2 >25% -1 STelevation, 2 ECGs/lBOmin 60-90min 45 84 97 43 79/86 Angiography before final 
worst lead ECG assessment 
Hogg et alI3 2 50% J ST elevation, 2 ECGs/300min 45-90min 17 82 93 67 93167 Angiography before final 
worst lead ECG assessment 
Nicolau et alI4 250% 1 ST elevation, 8 ECGsl48 hr <72 hr 101 49 58 83 92/37 Not suitable for early 
worst lead patency assessment 
within 4 hr after throm- 
bolysis 
Barbash et all5 2 50% i Z ST elevations 2 ECGs160 min 72 hr 286 66 87 76 87/76 Not suitable for early 
patency assessment 
Richardson 22 mm J STelevation, 9 ECGs/lBO min 6 days 188 56 67 80 92140 Not suitable for early 
et alI6 worst lead patency assessment 
or resolution within 30 
min 
*Sensitivity and specificity given for patency assessment. Positive predictive value: predictive value for patency. Negative predictive value: predictive value for occlusion. 
ECG = electrocardiogram; Pt. = patients; ? 1 = unspecified decrease. 
natural evolution of an acute myocardial infarc- 
tion.&lO Thus, rapid resolution of ST-segment eleva- 
tion is a marker of reperfusion. However, more 
recent studies, using serial 12lead ECG, have 
questioned the reliability of ST-segment changes to 
predict reperfusion. 2,3 Only recently, when newer 
techniques, such as continuous multilead ECG 
monitoring, became available could distinct pat- 
terns of ST-segment behavior be recognized as 
predicting reperfusion and patency after thrombo- 
lytic therapy. 
Serial l2-lead ECG recording@: Studies that 
evaluated the usefulness of ST-segment recovery 
from serial 1Zlead ECGs as a marker of reperfu- 
sion are presented in Table I.3J1-16 For proper 
comparison, angiographic assessment should be 
performed immediately after, and not before, the 
final serial ECG assessment. Further, assessment 
of patency is most important during the first few 
hours following thrombolytic therapy. Unfortu- 
nately, 3 studies appear invalid because of late 
angiography,1616 and in 2, angiography was planned 
before final ECG assessment.12,13 Finally, another 
study3 did not clearly define the criteria for ST 
recovery. Thus, the study by Clemmensen et ali1 
appears to be the most valid. This study comprised 
53 patients with an acute myocardial infarction 
treated with thrombolytic therapy. Two serial ECGs 
were recorded, one on admittance and the other 
approximately 180 minutes after the initiation of 
thrombolytic therapy. Directly following the second 
ECG, angiographic patency was assessed, using the 
classification of the Thrombolysis in Myocardial 
Infarction (TIMI) trial at first injection of contrast 
material.17 Reduction of the summed ST-segment 
elevation by 220% within 180 minutes rendered 
sensitivity and specificity values of 88% and 80% 
for ECG versus angiographic patency assessment, 
respectively. 
On average, looking at the results of the studies 
on early patency assessment using serial 12-lead 
ECGs, it appears that a rapid reduction of ST- 
segment elevation or depression by 220-50% of 
the highest previous ST value, occurring within 3 
hours from start of thrombolytic therapy, is a 
reasonably accurate predictor of reperfusion, 
whereas lack of rapid ST-segment recovery sug- 
gests occlusion. Depending on the severity of ST 
elevation on the initial ECG, the use of either the 
single lead with maximal ST deviation (“worst 
lead”) or the summed lead ST changes may be of 
importance. If a large ST deviation is present on 
the initial ECG, the ST reduction read at the single 
worst lead is preferable, although the reduction of 
the summed ST deviation may be more useful in 
cases of mild ST deviation. 
The conflicting results of these studies reflect 
the limitations of serial 1Zlead ECG recording for 
prediction of reperfusion and patency. Coronary 
reperfusion is a dynamic, rapidly changing process 
that is often accompanied by intermittent or sus- 
tained reocclusion and cyclic flow changes.18y1g One
third of episodes of recurrent ST elevation are 
silent and may remain unrecognized unless continu- 
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ous ECG monitoring is performed (Figure 1). 
These changes may remain unrecognized if serial 
ECG recording is used for monitoring. The time 
interval of the serial ECGs may be crucial for 
accurate detection of reperfusion and for interpre- 
tation of the coronary status. For example, if an 
undetected delayed ST (re)elevation peak pre- 
cedes the moment of ST-segment elevation recov- 
ery, serial ECG recording may suggest an occluded 
artery if the serial measurement is taken just 
before the rapid decline. On the other hand, if a 
serial ECG is taken at the moment of a reelevation 
episode that followed the first period of ST recov- 
ery, initial patency following thrombolysis will be 
missed (Figure 2). Because treatment strategies 
should nowadays be based on the presence or 
absence of initial reperfusion, this time resolution 
problem may lead to erroneous decision making. 
Therefore, it is more convenient to use continuous 
ECG monitoring techniques to avoid less accurate 
assessments of reperfusion and patency. 
Continuous ECG monitoring Wchniques: Sev- 
eral continuous ECG monitoring techniques have 
been evaluated for the assessment of reperfusion 
and patency. Holter ST-segment recording is the 
easiest technique to monitor the ST segment con- 
tinuously. However, it has some major limitations. 
Firstly, only a restricted number of leads can be 
monitored, which may not always reflect the area 
with maximal ST deviation. Further, Holter ST 
monitoring allows retrospective analysis only. This 
makes immediate feedback impossible and thus 
the technique cannot be used for on-line ST- 
segment monitoring and tailoring of thrombolytic 
therapy. This may explain why only a few studies 
have evaluated this technique for early patency 
assessment. The only 2 representative studies are 
those from Hohnloser et al4 and Krucoff et aJ20 
mentioned in Table II. Both studies demonstrate 
that Holter ST-segment recording may be used for 
ischemia monitoring. However, apart from the 
possibility to study reperfusion and (re)occlusion 
patterns retrospectively, the technique offers no 
major advantages above serial ECG monitoring. 
More recently, computer-assisted continuous 
multilead ECG monitoring techniques have be- 
come available for real-time noninvasive patency 
assessment. These techniques use continuous ECG 
sampling and averaging techniques, offering a con- 
tinuous real-time accurate measurement of the 
QRS complex and ST segments. 
Two different approaches for computer-assisted 
ECG analysis have been developed: continuously 
updated multilead ST monitoring, based on on-line 
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pemnanent reperfask4n ofthe Infarcted area (D-E). 
analysis of the conventional 1Zlead ECG, using 
either the single lead or the summed ST level (ELI, 
Mortara Instrument, Milwaukee, WI)21 and con- 
tinuous vectorcardiographic monitoring. The latter 
technique offers the possibility of both studying 
on-line vectorcardiographic QRS-complex and ST- 
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TABLl II Continuous Electrocardiographic Monitoring to Predict Coronary Repetfusion After Thrombolysis Therapy 
Positive/ 
Interval Pt. with Sensi- Speci- Negative 
Thrombolysis No Criteria tivity ficity Predictive Comment 
Study Technique Criteria to Angiography Pt. (%I (%I (%) Value (%I on Study 
Hohnloser et al4 Halter 250% 1 STelevation 1 of 60-90 min 82 48 60 95 97/42 Only 2 leads, short assess- 
2 leads within 90 min ment interval 
after thrombolysis 
Krucoff et aI20 Holter Achievement of ST steady 100 min 36* 56 89 82 85/87 Less confined criteria, 
state within 100 min af- selected group of patients 
ter thrombolysis 
Krucoff et alI9 Continuous 12 lead ~50% J or reelevation <6hr 22 ? 90t 927 ? Large, not defined assess- 
single lead or sum of ST ment interval, small study 
at contrast medium injec- 
tion 
Dellborg et ala* Vectorcardiography QRSVD and STVM qualita- At least 15 min 21 76 94 80 94/80 Pilot study, assessment 
tive evaluation interval not defined 
QRSVD increase 2 0.1 pV/ 21 86 94 40 83167 
min, plateau <2 hr 
Dellborg et ala4 Vectorcardiography QRSVD increase z 0.1 JLV/ 90min 96 65 83 73 89/61 Correct study design, short 
min, plateau <2 hr assessment interval 
STVM decrease t 0.83 
~V/min qualitative evalu- 
ation 
‘Totally occluded vessel at initial angiography. 
tsensitivity and specificity for assessment of occlusion. 
QRSVD = QRS vector difference; STVM = STvector magnitude. ? = unspecified. For other explanations and abbrewations, see Table I. 
1 
segment changes simultaneously (MidalOOO and 
Coronet, Ortivus Medical, Taby, Sweden).22 
Using these continuous digital monitoring tech- 
niques, 5 distinct patterns of ST-segment behavior 
following thrombolysis have been observed19*22: (1) 
rapid ST recovery without reelevation; (2) rapid ST 
recovery following a delayed ST-elevation peak; 
(3) persistent ST elevation without a recovery 
pattern; (4) rapid ST recovery followed by recur- 
rent ST elevation; and (5) a delayed ST-elevation 
peak followed by a rapid ST recovery and recurrent 
ST elevation. The first 3 patterns may point directly 
to the status of the infarct-related vessel. Rapid ST 
recovery without reelevation or a rapid ST recovery 
following a delayed ST-elevation peak both appear 
to be highly suggestive of reperfusion of the infarct- 
related artery, whereas persistent ST elevation 
without a recovery pattern suggests persistent occlu- 
sion, provided that significant ST elevation is 
present at the start of the monitoring period. 
Rapid ST recovery followed by recurrent ST eleva- 
tion or a delayed ST-elevation peak followed by a 
rapid ST recovery and recurrent ST elevation may 
be less specific and may suggest unstable reperfu- 
sion. Patency assessment may then be difficult. 
In Table II the 3 studies using continuous multi- 
lead and vectorcardiographic monitoring are listed. 
Krucoff et all9 recently reported on either the 
presence of 1 episode of 2 50% ST recovery (worst 
single lead or the summed ST deviation of all 12 
leads), its absence, or recurrent ST elevation, using 
continuous updated 12-lead computer-assisted ST 
monitoring. Absence of ST recovery or reelevation 
at the moment of angiographic assessment pre- 
dicted occlusion of the infarct-related vessel with 
sensitivity of 90% and specificity of 92%. However, 
the time interval between hookup and final ECG 
and angiographic assessment was rather long, up to 
6 hours, making assessment easier and only 22 
patients were studied. Dellborg et a122-24 reported 
on vectorcardiographic assessment of reperfusion 
and patency. All of their studies used both QRS- 
vector difference and ST-vector magnitude changes 
for prediction of patency. In a pilot study of 21 
patients, sensitivity and specificity for patency at 
angiography were 94% and 80%, respectively, if a 
rapid change of both the QRS-vector difference 
and the ST-vector magnitude was observed, ending 
in a steady state. If only the QRS-vector difference 
changes were used, sensitivity remained 94%, but 
specificity dropped to 40%.23 
In a recent study, preliminarily reported in an 
abstract form and recently submitted for publica- 
tion, Dellborg et a124 studied 96 patients using 
computer-assisted vectorcardiographic monitor- 
ing. More refined criteria were used and the 
angiographic assessment interval was fixed at 90 
minutes as much as possible. Sensitivity and speci- 
ficity for identification of patency were 81% and 
70%, respectively. 
How should the ECG be used to detect reper= 
fusion in clinical practice? On the basis of the 
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overall findings in the literature, it is suggested that 
a baseline ECG should be recorded or the patient 
should be hooked up to a continuous ECG monitor- 
ing system immediately on admittance to the hospi- 
tal. Obviously, hookup should not delay the start of 
therapy but should preferably be done before 
thrombolytic therapy has been initiated. The lead 
with maximal ST deviation should be used for ST 
monitoring. If less pronounced ST deviation is 
present, the sum of the ST deviations should be 
monitored. If only serial ECG recordings are used, 
short time intervals, < 10 minutes, should be cho- 
sen for ECG recordings until ST recovery has 
occurred and has stabilized (Figures 1 and 2). If no 
ST recovery is observed within 3 hours after the 
start of thrombolytic therapy, this will be highly 
suggestive of persistent occlusion. If continuous 
on-line ECG recording techniques are used, the 
detection of ST-segment recovery will be easier 
and also reelevation episodes may be observed 
more accurately, offering the possibility of applying 
early change of treatment strategy, if necessary. 
From the few studies on early patency assess- 
ment using ECG monitoring techniques, it may be 
deduced that rapid 150% ST recovery may prove 
to be the most valid criterion. However, ST-vector 
magnitude and QRS-vector difference changes 
may comprise complementary information on the 
coronary vessel status that are not yet studied in 
detail. The upcoming results of the Global Utiliza- 
tion of Streptokinase and t-PA for Occluded Arter- 
ies (GUSTO) trial, in which an ST monitoring 
substudy using both Holter, multilead, and vector- 
cardiographic ECG monitoring is included, will 
provide more information on which criteria and 
time intervals should be applied in order to predict 
more accurately reperfusion, patency, and (re)oc- 
elusion. 
ROLE OF CARDIAC SERUM PROTEINS 
It is generally accepted25-27 that, in case of 
successful reperfusion, cardiac enzymes appear 
earlier in the peripheral circulation, compared 
with unsuccessful reperfusion. Most studies on 
serum markers of reperfusion have been per- 
formed using serial measurements of creatine ki- 
nase (CK), its isoenzyme CK-MB, and myoglobin 
(Figures 3-5). 
Creative kinase and creathe kinase MB: 
Cytoplasmic CK is a dimer (M, 86,000-89,000) 
consisting of 2 subunits: an M subunit (M, 43,000) 
and a B subunit (M, 44,500), each encoded by a 
separate gene.28 The subunits combine to give 3 
isoenzymes: CK-MM, CK-MB, and CK-BB.29 In 
CPK (u/L) 
----- Myoglobin (pg/L) 




patients with an acute myocardial infarction, blood 
CK and CK-MB levels become abnormal 6-8 hours 
after infarction, peak in 12-24 hours, and become 
normal approximately 48 hours after infarction.30 
CK and/or CK-MB determinations are usually 
available on a stat basis in emergency laboratories. 
Most laboratories make use of an enzymatic method 
for total CK. The CK assay is a European Standard- 
ized Method that can easily be adapted on auto- 
mated clinical chemistry analyzers. Results are 
available in 15-20 minutes. CK-MB activity is 
frequently measured after polyclonal immunoinhi- 
bition of the M subunit. This method is also easily 
applicable on routine clinical chemistry analyzers 
and results are produced in 15-20 minutes. False 
high CK-MB activities are produced in case of 
hemolysis because of adenylate kinase interference 
and in case of presence of macroCK. Conse- 
quently, immunologic CK-MB mass assays (e.g., 
A 
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CK-MB on IMx, Abbott; CK-MB on Stratus, Bax- 
ter) gain interest nowadays because these methods 
are specific and do not suffer from macro-CK nor 
from adenylate kinase interference. Results can be 
produced in 20-45 minutes, depending on the type 
of immunoassay. 
Lewis et aP1 described a rapid initial absolute 
increase in plasma CK and CK-MB activities (units 
per liter per hour) following reperfusion. The 
authors calculated a mean relative first-hour in- 
crease of plasma CK activity of 34 ? 18% 
(mean + SD) of the peak increase (range, 13- 
67%) and a relative first-hour increase in CK-MB 
activity of 27 -+ 13% of the peak increase (range, 
13-57%) in patients that evolved from total occlu- 
sion to TIM1 flow grade 3 of the infarct-related 
artery. When reperfusion was incomplete or not 
achieved, the relative increase for CK and CK-MB 
was <6% of the peak rise in the last hour of the 
2.5-hour sampling period. The authors claim that 
0.5 hourly determinations of CK and CK-MB 
during 2.5 hours following start of thrombolysis 
provide a useful tool for recognition of reperfusion. 
Shortcomings of these indices are that (1) absolute 
rates of increase of CK and CK-MB activities are 
dependent on the assay temperatures used, and (2) 
measuring the relative rates of increase requires 
knowledge of the peak increase, which becomes 
available only several hours later. Also, (3) the 
rapid and augmented release of CK with reperfu- 
sion has been associated with large, hemorrhagic 
infarcts in some dog models.32 
Gore et aP3 described early peak CK as a 
reperfusion index in patients’with acute myocardial 
infarction. In the nonreperfused group (TIM1 flow 
mV w/ml 
u/l Angie 8 PTCA 
1.0 - 500 J- Angio: 
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grade 0 or 1) the mean time-to-peak (TTP) from 
onset of symptoms was 20.1 hours. In patients who 
achieved reperfusion (TIM1 2 or 3) the mean TTP 
was 14.3 hours. In the nonreperfused group, the 
mean TTP from onset of pain was 16.1 hours and 
this did not differ significantly from the TTP of the 
reperfused group. Peaking of plasma CK within 4 
hours after starting thrombolysis is highly sugges- 
tive of reperfusion. Late peaking, > 16 hours after 
starting thrombolysis, rarely indicated reperfusion. 
A’major drawback of this reperfusion index is the 
considerable overlap of the TTP ranges in the 
reperfused and occluded patient groups between 4 
and 16 hours. Another limitation of TIP CK as a 
reperfusion index is the overestimation of drug- 
induced reperfusion by including patients who had 
a subtotal occlusion at the time of treatment. 
Garabedian et aP4 documented that a > 2.5-fold 
increase in CK-MB levels at the end of a 90-minute 
recombinant issue-type plasminogen activator (rt- 
PA) infusion provided evidence for reperfusion of 
the left anterior descending coronary artery (sensi- 
tivity of 93% and specificity of 83%) and that a 
> 2.2-fold increase in CK-MB levels could identify 
reperfusion of the right coronary artery (sensitivity 
of 89% and specificity of 100%). Slightly different 
cutoff points were proposed because of the greater 
prevalence of well-developed collateral circulation 
in the right coronary artery circulation bed. Failure 
of this CK-MB increase ratio to detect reperfusion 
may result from initial presence of subtotal occlu- 
sion, well-developed collateral circulation, or cyclic 
reperfusion and reocclusion. 
Cre&ine klnase isofonns: Zonal electrophore- 
sis is widely used for separation of CK-MM, CK- 
MB, and CK-BB in the routine clinical chemistry 
laboratory. 29 Prolonging the CK isoenzyme lectro- 
phoresis time, increasing the voltage, or using 
isoelectric focusing revealed at least 3 isoforms of 
CK-MM (denoted CK-MMlm3 or CK-31-3) and at 
least 2 isoforms of CK-MB (denoted CK-MBI-2 or 
CK-21-2).35a The CK isoforms are no true isoen- 
zymes but result from post-translational modifica- 
tion in serum of the CK-M subunit by a CK 
conversion factor, i.e., carboxypeptidase N.41 In 
case of CK-MM3, the tissue isoform, hydrolytic 
cleavage of the carboxy-terminal lysine gives rise 
sequentially to CK-MM2 and CK-MM1 (most an- 
odal fraction). CK-MB2 is converted to CK-MBi. 
The discovery of probably 3 isoforms for CK-MB is 
recent and yet no commercialized methods exist 
that recognize these 3 CK-MB isoforms.42143 
The interpretation of electrophoresis data of 
serum CK following acute myocardial infarction 
has been complicated because of contradictions in 
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nomenclature. The International Union of Pure 
and Applied Chemistry-International Union of 
Biochemistry (IUPAC-IUB) Commission on No- 
menclature prescribes that the most anodal isoen- 
zyme should be identified with the lowest arabic 
numerical, i.e., CK-BB = CK-1, CK-MB = (X-2, 
and CK-MM = CK-3. In practice, letter subscripts 
have been replaced by numbers: CK-MB = CK-2 
and the anodal conversion is represented by 
CK-22 + CK-21.29,44 
The reperfusion results after induced acute 
myocardial infarction in dogs suggested that prompt 
detection of reperfusion is possibly based on analy- 
sis of sequential changes in the plasma CK-MM 
isoform activities.45J46 CK isoforms are not usually 
routinely determined in most clinical laborato- 
ries.25 So far, different technologies have been 
applied to separate and quantitate the CK iso- 
forms.25,47-57 Analytical performance of these meth- 
ods is poorly documented,48 yet, electrophoresis is 
reported to be the most cost-effective, practical, 
reproducible, and sensitive method. However, dif- 
ferences in method specificity have also been 
reported, isoelectric focusing and high-voltage elec- 
trophoresis techniques being denaturating and pro- 
ducing artifacts (extra bands).48 
Although several of these methods allow for 
45minute turn-around times, none is suitable for 
stat analysis because they are too laborious and 
specialized. Future potential for the clinical appli- 
cation of CK-MM and CK-MB isoforms depends 
on the development of simple, rapid, and auto- 
mated systems. Recently, a sufficiently automated 
high-voltage electrophoresis analyzer (REP, Hel- 
ena Laboratories, Beaumont, Texas)58 that fulfills 
these requirements has been introduced. Also, 
monoclonal antibodies specific to certain CK iso- 
forms became available.59-61 The future develop- 
ment of rapid, automated immunoassays that quan- 
titate specific isoforms may provide the basis for a 
new generation of immunoassay tests that distin- 
guish tissue isoforms from serum isoforms. 
CK-MM ISOFORMS: Seacord et a1’j2 found a marked 
increase of the percent CK-MM3 activity over the 
first hour postdosing in all patients with successful 
reperfusion. Apple et a140 found that the CK-MM3/ 
CK-MM1 ratio peaked significantly earlier than 
total CK and CK-MB in both reperfused and 
occluded individuals. Morelli et a163 confirmed 
these findings and documented that the TTP of the 
CK-MM3/CK-MM1 ratio in the first 3 hours post- 
dosing differentiated reperfused from nonreper- 
fused individuals (p <O.Ol). On the other hand, 
the serum appearance constant of CK-MM3 also 
differentiated successfully versus unsuccessfully 
reperfused patients with acute myocardial infarc- 
tion.63@ Puleo et a165 studied the rate of decline of 
plasma CK-MM3 levels over 18 hours after onset of 
infarction. They found a sensitivity of 87% and a 
specificity of 74% when a minimum rate of decline 
of 3.1% hr-l was exceeded. 
The group of Abendschein et a1’j6 reported that 
conjoint analysis of percent CK-MM3 and myoglo- 
bin increases over the first hour following initiation 
of thrombolysis, when these increases exceeded 
0.18% min-l and 2.6 ng/mL min-l, respectively, 
provide robust noninvasive criteria for reperfusion 
evaluation. 
In summary, (1) the determination of the rate of 
decrease of percent CK-MM3 is less suitable for 
reperfusion evaluation because of the requisite 
time delay (preventing additional interventions to 
salvage myocardium at a time when this can be 
initiated effectively), and because it is influenced 
by the residual stenosis grade and the amount of 
collateral blood flow. (2) Determination of the 
TIP of the percent CK-MM3 and the appearance 
constant (K,) of CK-MM3 are impractical as reper- 
fusion indices because of the requisite time delay 
and repeated blood sampling necessary to establish 
the peak or to calculate K,. (3) The rate of increase 
of the percent CK-MM3 or CK-MMs/CK-MM1 
ratio is superior for reperfusion evaluation. The 
rate of increase of percent CK-MM3 is the earliest 
available reperfusion index because only 2-3 plasma 
specimens, sampled before and within 1 hour after 
starting thrombolysis, are required. 
CK-MB ISOFORMS: CK-MM and its isoforms lack 
cardiac specificity; in contrast, CK-MB isoforms 
are more cardiac specific.67,68 Until recently, avail- 
able MB isoform assays lacked the necessary ana- 
lytical sensitivity to detect CK-MB isoforms in 
normal plasma,47,48 yet sensitive assays with good 
analytical performance are available.49a69 Christen- 
son et a168 found that the CK-MBJCK-MB1 ratio 
peaked 90 minutes after starting thrombolysis, 
compared with the 2-hour time to peak for the 
CK-MM3/CK-MM1 ratio in the study of Morelli et 
a1.63 Puleo et a170 concluded that the CK-MB2/CK- 
MB1 ratio provided the best discrimination be- 
tween reperfused and nonreperfused individuals 
within 1 hour after onset of pain. The limited body 
of clinical data on the utility of CK-MB isoform 
indices for reperfusion evaluation needs to be 
extended in order to understand their future poten- 
tial. Especially, the existence of perhaps 3 CK-MB 
isoforms must be clarified.42,43 
Myoglobin: Myoglobin is a cytosolic hemopro- 
tein in cardiac and skeletal muscles (M, 17,700) 
necessary for the last step in the oxygen transport 
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to the mitochondria.71*72 Normal serum levels of 
myoglobin are reported to be in the range of 6-85 
ng/mL and 4-60 ng/mL for men and women, 
respectively. 3o After acute myocardial infarction, 
the serum concentration of myoglobin becomes 
abnormal in about 2 hours, peaks in about 6-9 
hours, and becomes normal in 24-36 hours. Myoglo- 
bin increases up to 10 times the baseline level. 
Renal impairment, vigorous exercise, and many 
other conditions can influence the serum myoglo- 
bin levels.30 Myoglobinemia has also been de- 
scribed to be useful for evaluation of skeletal 
muscle damage .73*74 The advantage offered by myo- 
globin as a marker for myocardial injury is that it 
appears earlier in the peripheral blood circulation 
compared with CK, CK-MB, and the CK iso- 
forms.75-80. 
Myoglobin kinetics after coronary artery liga- 
tion and subsequent reperfusion in dogs show a 
rapidly evolving time pattern, with peak concentra- 
tions at 45 minutes after vessel reopening.81 De- 
spite its interesting kinetics, the myoglobin measure- 
ment has not been used extensively in the past. 
Reasons were the lack of reliable, rapid, and 
automated myoglobin assays,47 as well as the poor 
specificity of the protein (60-95%), with large 
amounts being present in skeletal muscle. In the 
past a complement fixation test, numerous radioim- 
munoassays, and a semiquantitative latex test have 
been developed. Recently, however, stat immuno- 
assays have been introduced on the European 
market.82>83 Behring Diagnostics (Behringwerke, 
Marburg, Germany) commercialized 2 myoglobin 
immunoassays: (1) an automated nephelometric 
fixed-time method with NA-latex myoglobin re- 
agent on a BNlOO or BNA nephelometer (Behring 
Diagnostica) that produces results within 20 min- 
utes (12 minutes analysis time); and (2) a manual 
turbidimetric immunoassay on the precalibrated 
Behring Turbitimer with Turbiquant myoglobin 
reagent that produces results within 180 seconds. 
The latter reagent can also be applied on routine 
clinical chemistry analyzers that are capable of 
measuring optical turbidity at 340 nm. Also, a 
l-step 2-site particle concentration fluorescence 
immunoassay using monoclonal antibodies has been 
described.84 
Kinetics of myoglobin appearance depend on 
infarct reperfusion and TIM1 flow grade scores. 
Differences in kinetics between reperfused and 
nonreperfused arteries in patients with acute myo- 
cardial infarction will be reflected by different TTP 
values, different peak levels, and different rates of 
increase. 
Ellis et algo found a mean TTP of 111 minutes 
and 360 minutes in the reperfused and nonreper- 
fused groups, respectively. They described a mean 
T25-1~ (i.e. the time required for myoglobin to 
increase from 25% to 100% of the peak level) of 71 
and 341 minutes in the reperfused and nonreper- 
fused groups, respectively. A > 4.6-fold increase 
the first 2 hours following initiation of thrombolysis 
correctly identified 85% of the reperfused patients 
and 100% of the nonreperfused patients. 
Katus and coworker$ determined the predic- 
tive power of the TI’P values of myoglobin, CK, 
and CK-MB in their recanalization study. In case 
of recanalization <3.5 hours after onset of chest 
pain, the probability of correct classification varied 
between 90-100%. In case of late reperfusion, the 
probability of correct classification ranged between 
5-99%. Myoglobin allowed the earliest and best 
discrimination between reperfused and nonreper- 
fused individuals. These findings fit with the data 
of McCullough et a1,86 who also concluded that 
TTP analysis of myoglobin is not useful as a 
reperfusion index because of the large overlap of 
TTP values for reperfused and nonreperfused 
patients. 
Clemmensen et als7 also evaluated TIP of 
myoglobin as a reperfusion index and concluded 
that peak myoglobin levels reached within 4 hours 
after starting thrombolysis accurately predict coro- 
nary reperfusion with 91% sensitivity and 88% 
specificity, and this within the time limit in which 
rescue angioplasty is still effective. 
Ishii et alg8 calculated a myoglobin and CK-MB 
ratio (defined as the ratio of the level at 15, 30, or 
60 minutes after reperfusion to the level before 
reperfusion). The predictive accuracy of a myoglo- 
bin ratio > 2.4 at 15 minutes was 96%; for CK-MB 
the predictive accuracy of a CK-MB ratio > 2 at 15 
minutes was only 68%. Consequently, the myoglo- 
bin ratio at 1.5 minutes was found to be a reliable 
marker of reperfusion and more useful than CK-MB 
for detection of reperfusion within 30 minutes. 
Dillon et alg9 calculated and estimated myoglo- 
bin appearance rates (estimated & = rate of myo- 
globin increase over the first hour to myoglobin at 
the time of application of therapy). A significantly 
higher mean K, was found in the reperfused group 
(0.122 + 0.182 min- r [mean 2 SD]) versus the non- 
reperfused group (0.005 + 0.003 min-‘). 
CONCLUSION 
Continuous multilead ST monitoring tech- 
niques are of clinical use for prediction of vessel 
status early after myocardial infarction. In addi- 
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tion, with the introduction of myoglobin as a l6. Richardson SG, Morton P, Mutt@ JG, Scott ME, Q’Keeffe DB. Relation 
biochemical parameter, a real-time relation with of coronary arterial patency and left ventricular function to electrwardio- graphic changes after streptokinasc treatment during acute myocardial infarc- 
electrical events during acute mvocardial infarc- tion.Am .I Cardioi 1988;61:%1-965. 
tion and subsequent reierfusion ban be observed. 17. The TIM1 Study Group: The Thrombolysis n Myocardial Infarction (TIMI) 
Consequently, myoglobin seems to be the monitor- 
Trial. N Engl J Med 1985;312:932-936. 
18. K won K, Freedman SB, Wilcox I, Allman K, Madden A, Carter GS, 
ing biochemical parameter of choice for the evalu- 
ation of coronary reperfusion within the time limits 
during which additional therapeutical interven- 
tions are feasible and effective. 
Future studies are needed to prove if the com- 
bined evaluation of clinical, electrocardiographic, 
and enzymatic monitoring will provide the optimal 
information for assessing coronary patency after 
thrombolysis. 
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